Relmada Therapeutics (RLMD) Non Operating Income (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Non Operating Income for 13 consecutive years, with $409798.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 37.81% year-over-year to $409798.0; the TTM figure through Mar 2026 stood at $1.5 million (down 57.02% YoY), while the FY2025 annual figure was $1.7 million, down 56.16% from the prior year.
• Non Operating Income fell to $409798.0 in Q1 2026 per RLMD's latest filing, from $465352.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $5.6 million in Q2 2022 and bottomed at -$1.4 million in Q1 2022.
• Historically, Non Operating Income has averaged $891312.7 across 5 years, with a median of $690580.0 in 2023.
• On a YoY basis, Non Operating Income climbed as much as 6292.38% in 2022 and fell as far as 1536.53% in 2022.
• Relmada Therapeutics' Non Operating Income stood at $758055.0 in 2022, then jumped by 119.53% to $1.7 million in 2023, then slumped by 74.86% to $418418.0 in 2024, then grew by 11.22% to $465352.0 in 2025, then decreased by 11.94% to $409798.0 in 2026.
• Business Quant data shows RLMD's Non Operating Income at $409798.0 in Q1 2026, $465352.0 in Q4 2025, and $235850.0 in Q3 2025.